Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing

By Reuters News

- Ultragenyx Pharmaceutical Inc. RARE.O:

  • ENTERS SETTLEMENT AGREEMENT WITH NAVINTA ON DOJOLVI PATENT LITIGATION - SEC FILING

  • NAVINTA LICENSED TO MARKET GENERIC DOJOLVI FROM JANUARY 1, 2033 - SEC FILING

  • LICENSE PERIOD MAY EXTEND TO JULY 1, 2033 IF PEDIATRIC EXCLUSIVITY GRANTED - SEC FILING

  • SIMILAR PATENT LITIGATION AGAINST OTHER DOJOLVI ANDA FILERS RELATED TO DOJOLVI REMAINS PENDING - SEC FILING

Source text: [ID:n0001193125-26-424739]

Further company coverage: RARE.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk